Company intelligence / Profile preview
Keymed Biosciences
Chengdu, Sichuan, Chinaen.keymedbio.com ↗
- Ownership
- Public · 2162.HK
- Employees
- ~1116
- Development stage
- Other
01
Overview
Keymed has built a diversified pipeline focused on innovative biological therapies for autoimmune diseases and oncology. The company’s lead assets include CM310, CM326, CM313, and CM383 for type II immunological diseases. Several programs are in mid-to-late stage clinical development. The company leverages an integrated R&D platform to accelerate biologics innovation.
- Therapeutic areas
- ImmunologyNeurologyOncology
- Modalities
- monoclonal antibodies (mAbs)bispecific antibodiesantibody-drug conjugates (ADCs)therapeutic proteins
- Industry
- Biotech
02
Drug pipeline
16 assets15 more assets in the full pipeline.
03
Partnerships
InnoCare Pharma
04
Financials
- Market cap
- $2.3B
- Total revenue
- $104.6M
- Enterprise value
- $1.9B
Beyond the preview
Go deeper on Keymed Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Keymed Biosciences.